Methaniazide/thioacetazone
| Combination of | |
|---|---|
| Methaniazide | Antibiotic |
| Thiacetazone | Antibiotic |
| Legal status | |
| Legal status |
|
Methaniazide/thioacetazone, sold under the brand name Neothetazone, is an antibiotic combination of methaniazide (neotizide) and thioacetazone that is or was very commonly used in the treatment of tuberculosis.[1] It has been implicated as a cause of gigantomastia in a single 1970 case report,[2][3] and, along with D-penicilliamine, bucillamine, ciclosporin, and indinavir, is one of the only drugs to have been associated with gigantomastia.[2][3][4][5]
See also
References
- ↑ SAMJ. Medical Association of South Africa. 1970. pp. 449–450.
Diffuse hypertrophy of the breasts seems to have been associated in this patient with treatment with Neothetazone, which consists of neotizide and thiacetazone, and which is very commonly used in the treatment of tuberculosis.
- 1 2 Sakai Y, Wakamatsu S, Ono K, Kumagai N (2002). "Gigantomastia induced by bucillamine". Annals of Plastic Surgery. 49 (2): 193–5. doi:10.1097/00000637-200208000-00013. PMID 12187348.
Drug-induced mammary hyperplasias have been reported as rare complications of D-penicillamine and Neothetazone. [...] It is rare for breast hypertrophy to be induced by drugs. In particular, gigantomastia has been reported to be induced by only two drugs: D-penicillamine and the antibiotic neothetazone. [...] In 1970, drug-induced gigantomastia was reported for the first time by Scott.4 It was induced by the antibiotic Neothetazone.
- 1 2 Dancey A, Khan M, Dawson J, Peart F (2008). "Gigantomastia--a classification and review of the literature". Journal of Plastic, Reconstructive & Aesthetic Surgery. 61 (5): 493–502. doi:10.1016/j.bjps.2007.10.041. PMID 18054304.
- ↑ S. Eva Singletary; Geoffrey L. Robb; Gabriel N. Hortobagyi (2004). Advanced Therapy of Breast Disease. PMPH-USA. pp. 20–. ISBN 978-1-55009-262-2.
- ↑ Mario Lima (27 September 2013). Pediatric Thoracic Surgery. Springer Science & Business Media. pp. 316–. ISBN 978-88-470-5202-4.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.